ReviewCancer metastasis reviews2010
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy.
Review in Cancer metastasis reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 90 citations in OpenAlex.
- Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer.Cancer research and treatment · 2017Trial
- Identification of MUC5B as a lymph node metastasis-associated gene in lung adenocarcinoma through integrated transcriptomic and machine learning approaches.Frontiers in immunology · 2025Article
- Involvement of HDAC2-mediated kcnq2/kcnq3 genes transcription repression activated by EREG/EGFR-ERK-Runx1 signaling in bone cancer pain.Cell communication and signaling : CCS · 2024Article
- Deep Learning-Based H-Score Quantification of Immunohistochemistry-Stained Images.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024Article
- Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma.Communications biology · 2020Article
- Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma.Journal of pathology and translational medicine · 2020Article
- LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression.Journal of cellular and molecular medicine · 2019Article
- Pathways regulating the expression of the immunomodulatory protein glycodelin in non‑small cell lung cancer.International journal of oncology · 2019Article
- Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion.Oncotarget · 2017Article
- Advances in targeting the transforming growth factor β1 signaling pathway in lung cancer radiotherapy.Oncology letters · 2017Article
- Polymorphisms in genes related to epithelial-mesenchymal transition and risk of non-small cell lung cancer.Carcinogenesis · 2017Article
- Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.Molecular diagnosis & therapy · 2017Article
- Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer.Oncology letters · 2017Article
- MLK3 Signaling in Cancer Invasion.Cancers · 2016Review
- Article
- Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far.Therapeutics and clinical risk management · 2016Review
- Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.Cell death & disease · 2015Article
- A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction.International journal of oncology · 2015Article
- Downregulation of ubiquitin inhibits the proliferation and radioresistance of non-small cell lung cancer cells in vitro and in vivo.Scientific reports · 2015Article
- Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.International journal of oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths in the USA and worldwide. Most patients present with advanced disease, and treatment options for these patients are generally limited to platinum-based chemotherapy and a few targeted therapies. Targeted agents currently in use for NSCLC inhibit oncogenic receptor tyrosine kinase pathways, such as the epidermal growth factor receptor (EGFR) pathway. While current EGFR-targeted agents, including erlotinib and gefitinib, may result in dramatic responses, they demonstrate efficacy in only a fraction of patients, and resistance to these agents frequently develops. In order to select patients most likely to benefit from blockade of EGFR pathways, investigators have focused on identifying molecular correlates of response to anti-EGFR therapy. New strategies to minimize the risk of resistance to EGFR inhibition have been employed in the development of next-generation EGFR tyrosine kinase inhibitors, such as PF00299804 and BIBW 2992; these include irreversibility of target binding, inhibition of multiple EGFR family receptors, and/or simultaneous inhibition of EGFR and other oncogenic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.